Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
Lancet (London, England)|February 10, 2015
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 studyJean-Michel Molina, Chloe Orkin, David M Iser, et al.
Journal of Hepatology|February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.
Gastroenterology|December 26, 2013
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis BScott Fung, Peter Kwan, Milotka Fabri, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
World Journal of Gastroenterology|December 8, 2011
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virusKeyur Patel, Mireen Friedrich-Rust, Yoav Lurie, et al.
Hepatology International|March 20, 2015
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsMaria Buti, Scott Fung, Edward Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Cell Reports. Medicine|April 19, 2023
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASHJake Conway, Maryam Pouryahya, Yevgeniy Gindin, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|February 10, 2015
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 studyJean-Michel Molina, Chloe Orkin, David M Iser, et al.
Journal of Hepatology|February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.
Gastroenterology|December 26, 2013
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis BScott Fung, Peter Kwan, Milotka Fabri, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
World Journal of Gastroenterology|December 8, 2011
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virusKeyur Patel, Mireen Friedrich-Rust, Yoav Lurie, et al.
Hepatology International|March 20, 2015
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsMaria Buti, Scott Fung, Edward Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Cell Reports. Medicine|April 19, 2023
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASHJake Conway, Maryam Pouryahya, Yevgeniy Gindin, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
Pageof 17